基底转移转换导致EGFR在人类肺部腺癌中产生治疗耐药性
Taro Shinozaki1, Kazuhiro Togasaki2,3,4, Junko Hamamoto1
1Division of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine, Tokyo, Japan.
Nature communications
|May 11, 2025
概括
研究人员发现了一种对肺癌药物耐药性的新机制. 由基因变化驱动的癌细胞的"基底转变"可以导致对EGFR-TKI的抵抗,这表明了新的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 表皮生长因子受体氨酸激酶抑制剂 (EGFR-TKI) 是EGFR突变肺腺癌 (LUAD) 的标准治疗方法.
- 对EGFR-TKI的治疗耐药性是一个重大的临床挑战,由各种遗传变异和未知因素驱动.
- 了解耐药机制对于开发有效的下一代疗法至关重要.
研究的目的:
- 综合调查LUAD中EGFR-TKI耐药性的基础分子机制.
- 建立和利用患者衍生LUAD器官的生物库进行耐药性研究.
- 为了识别超出已知的遗传突变的新型耐药性途径.
主要方法:
- 创建一个来自患者的EGFR突变肺癌器官的生物银行,这些器官来自于用EGFR-TKI治疗的患者.
- 对抗性有机体进行全面的分子分析,包括单细胞分析.
- 潜在的基因工程 (NKX2-1淘汰赛) 以验证已识别的途径.
主要成果:
- 识别一种缺乏已知的耐药性突变的EGFR-TKI耐药LUAD有机体的子组.
- 一个人的特征描述.
- 基本位移的变化
- 现型与混合LUAD和状细胞癌基因表达.
- NKX2-1敲击诱导的基位变换和EGFR-TKI抵抗.
- 基底转移LUAD经常显示CDKN2A/B损失和对CDK4/6抑制剂的敏感性.
结论:
- 一种新的基底转移表型有助于LUAD中的EGFR-TKI耐药性.
- 器官生物库是研究肺癌耐药性的宝贵资源.
- 向CDK4/6抑制剂可能对基底转移耐药的LUAD有效.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
10.1K
相关概念视频
02:38Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
02:56Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K